Teva Pharmaceutical Industries Limited (NYSE:TEVA) Q3 2024 Earnings Conference Call November 6, 2024 8:00 AM ET

Company Participants

Richard Francis - President & CEO
Eli Kalif - CFO
Eric Hughes - Head of R&D & Chief Medical Officer
Ran Meir - SVP, head of IR

Conference Call Participants

Umer Raffat - Evercore ISI
Balaji Prasad - Barclays
David Amsellem - Piper Sandler
Jason Gerberry - Bank of America
Chris Schott - J.P. Morgan
Ash Verma - UBS
Yifeng Liu - HSBC

Operator

Hello, and welcome to the Q3 2024 Teva Pharmaceuticals Industries Limited Earnings Conference Call. My name is Alex, and I'll be coordinating the call today. [Operator Instructions] I'll now hand it over to your host, Ran Meir, Senior Vice President, Head of Investor Relations. Please go ahead.

Ran Meir

Thank you, Alex, and thank you, everyone, for joining us today. We hope you have had a chance to review our Q3 results press release, which was issued earlier this morning. A copy of the press release, along with the Slides presented during this call, are available on our website at ir.Tevapharm.com. Please review our forward-looking statements on Slide 2. Additional information regarding these statements and our non-GAAP financial measures is available on our earnings release and in our SEC forms 10-K and 10-Q.

To begin today's call, Richard Francis, Teva's CEO, will provide an overview of Teva's third quarter business performance, recent events, and our focus and priorities going forward. Then, Dr. Eric Hughes, our Head of R&D and Chief Medical Officer, will discuss progress on our innovative pipeline. Our CFO, Eli Kalif, will follow up by reviewing the third quarter financial results and our updated financial outlook in more detail. Please note that today's call will run approximately one hour.

And with that, I will turn the call over to Richard. Richard, if you would, please.

Richard Francis

Thank you Ran, and good morning, good afternoon, everybody. Thank you for joining Teva's third quarter 2024 results. So, I'm going to walk you through a presentation today, which the backbone of it is in our pivot to growth strategy. And as you know, we launched this last year to get Teva back to growth and it's focused on four pillars, deliver on our growth engines, step up innovation, create a sustainable generics powerhouse, and focus the business. And through the presentation myself, Eric, and Eli will show the progress we're making across this strategy. But just to give you some sort of areas to focus on, as you'll see and deliver on our growth engines, we are driving strong performance with our innovative portfolio of AUSTEDO, AJOVY, and UZEDY. In step-up innovation, Eric will show you the great work his team have done of building a deep pipeline that's coming to fruition and we've got some exciting milestones and data points coming up in the near-term. And then on our sustainable generics powerhouse, you'll see the performance we have across all of our regions, and I'll give you a bit of context as to what's driving that and what's behind that. And then finally, focus the business. We're very pleased to see that some of the credit ratings have looked at Teva and see the future is brighter. And also, we'll give you an update on TAPI and the divestment process there.